Why the study?
Obese cancer patients have higher risk of chemotherapy cardiotoxicity, and omentin has shown cardioprotective effects against anthracycline-induced cardiomyocyte apoptosis, motivating evaluation of its effects against docetaxel toxicity.
Does omentin prevent docetaxel-induced cardiotoxicity in H9c2 cells?
Does omentin prevent docetaxel-induced cardiotoxicity in H9c2 cells?
Omentin protects H9c2 cardiomyoblasts against docetaxel-induced toxicity by inhibiting endoplasmic reticulum stress and apoptosis, highlighting its potential to mitigate chemotherapy-induced cardiotoxicity.
Omentin may reduce docetaxel cardiotoxicity risk in obese patients; leaves open whether supplementation improves outcomes in clinical settings.
BACKGROUND: Association between obesity and cardiovascular diseases is well known, however increased susceptibility of obese patients to develop several cancer types is not so commonly known. Current data suggest that poorer overall survival in cancer patients might be associated to non-cancer-related causes such as higher risk of cardiotoxicity in obese patients treated with chemotherapeutic agents. Omentin, a novel adipokine decreased in obesity, is actually in the spotlight due to its favourable effects on inflammation, glucose homeostasis and cardiovascular diseases. Also, recent data showed that in vitro anthracycline-induced cardiomyocyte apoptosis is counteracted by omentin suggesting its cardioprotective role. OBJECTIVE: Our aim was to evaluate omentin effects against docetaxel toxicity. RESULTS: Our data indicate that omentin inhibits docetaxel-induced viability loss and that increased viability is associated to decreased caspase-3 expression and cell death. Although omentin reduces NOX4 expression, it failed to reduce docetaxel-induced reactive oxygen species production. Our results indicate that omentin decreases docetaxel-induced endoplasmic reticulum stress, suggesting that cardioprotective role might be associated to ERS inhibition. CONCLUSION: These data suggest that omentin treatment may contribute to decrease susceptibility to DTX-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Lage et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: